Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use FASLODEX safely and effectively. See full prescribing information for FASLODEX. FASLODEX® (fulvestrant) injection, for intramuscular useInitial U.S. Approval: 2002
Medication labelWhy this: Advisory · dailymed-prescription
Monotherapy FASLODEX is indicated for the treatment of: •Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or •HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy FASLODEX is indicated for the treatment of: •HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. •HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
- generic_name
- fulvestrant
- product_names
- Fulvestrant
- ndc
- 0310-0720, 0310-0720-10
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en